Addition of anti-CD25 to thymoglobulin for induction therapy: Delayed return of peripheral blood CD25-positive population

Clinical Transplantation

Volumn 25, Issue 2, 2011, Pages

  Sageshima, Junichiro ^a   Ciancio, Gaetano ^a   Gaynor, Jeffrey J ^a   Chen, Linda ^a   Guerra, Giselle ^a   Kupin, Warren ^a   Roth, David ^a   Ruiz, Phillip ^a   Burke, George W ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

IL 2 receptor; Kidney pancreas transplant; T cells; Type 1 diabetes

Indexed keywords

DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ARTICLE; CD25+ T LYMPHOCYTE; FLOW CYTOMETRY; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; PANCREAS TRANSPLANTATION; T-LYMPHOCYTE SUBSETS;

EID: 79953321610     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01360.x     Document Type: Article

References (20)

1. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007: 21: 1387.
2. Goggins WC, Pascual MA, Powelson JA et al. A prospective, randomized, clinical trial of intraoperative versus postoperative. Thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 2003: 76: 798.
3. Burke GW III, Kaufman DB, Millis JM et al. Prospective, randomized trial of the effect of antibody induction in simultaneous pancreas and kidney transplantation: three-year results. Transplantation 2004: 77: 1269.
4. Ciancio G, Burke GW, Gaynor JJ et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005: 80: 457.
5. Ciancio G, Burke GW, Gaynor JJ et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24months of follow up. Clin Transplant 2008: 22: 200.
6. Einecke G, Mengel M, Hidalgo L, Allanach K, Famulski KS, Halloran PF. The early course of kidney allograft rejection: defining the time when rejection begins. Am J Transplant 2009: 9: 483.
7. Turner SJ, La Gruta NL, Kedzierska K, Thomas PG, Doherty PC. Functional implications of T cell receptor diversity. Curr Opin Immunol 2009: 21: 286.
8. Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998: 338: 1813.
9. Naujokat C, Berges C, Fuchs D, Sadeghi M, Opelz G, Daniel V. Antithymocyte globulins suppress dendritic cell function by multiple mechanisms. Transplantation 2007: 83: 485.
10. Zand MS. B-cell activity of polyclonal antithymocyte globulins. Transplantation 2006: 82: 1387.
11. Ruggenenti P, Codreanu I, Cravedi P, Perna A, Gotti E, Remuzzi G. Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation. Clin J Am Soc Nephrol 2006: 1: 546.
12. Lan RY, Selmi C, Gershwin ME. The regulatory, inflammatory and T cell programming roles of interleukin-2 (IL-2). J Autoimmun 2008: 31: 7.
13. Afzali B, Lechler RI, Hernandez-Fuentes MP. Allorecognition and the alloresponse: clinical implications. Tissue Antigens 2007: 69: 545.
14. high cell population in solid organ transplant recipients. J Exp Med 2007: 9: 204.
15. Macedo C, Orkis EA, Popescu I et al. Contribution of naïve and memory T-cell populations to the human alloimmune response. Am J Transplant 2009: 9: 2057.
16. Hoyer KK, Dooms H, Barron L, Abbas AK. Interleukin-2 in the development and control of inflammatory disease. Immunol Rev 2008: 226: 19.
17. Cravedi P, Mannon RB, Remuzzi G. Lymphocyte depletion for kidney transplantation: back to the past? Nat Clin Pract Nephrol 2008: 4: 534.
18. Joffre O, Santolaria T, Calise D et al. Prevention of acute and chronic allograft rejection with CD4+ CD25+ Foxp3+ regulatory T lymphocytes. Nat Med 2008: 14: 88.
19. Lopez M, Clarkson MR, Albin M, Sayegh MH, Najafian N. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+, CD25+ Foxp3+ regulatory T cells. J Am Soc Nephrol 2006: 17: 2844.
20. Kreijveld E, Koenen HJPM, Klasen IS, Hilbrands LB, Joosten I. Following anti-CD25 treatment, a functional CD4+CD25+ regulatory T-cell pool is present in renal transplant recipients. Am J Transplant 2007: 7: 249.